Appili Therapeutics Announces Update to Funding Agreement with The Lind Partners
Pursuant to the previously disclosed financing agreement, Appili issued to Lind a guaranteed convertible security with a par value of
“Today’s deal is an important part of Appili’s short-term strategy to maximize balance sheet flexibility and ultimately increase shareholder value,” said Dr.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein. The securities offered have not been registered under the United States Securities Act of 1933, as amended (the ‘
This press release contains “forward-looking statements”. Whenever possible, words such as “could”, “would”, “could”, “should”, “should”, “anticipate”, “believe”, “plan”, “expect”, ” intend ”,“ estimate ”,“ potential of ”and similar expressions have been used to identify these forward-looking statements. These forward-looking statements include statements regarding the Company’s development plans for its product portfolio and expectations regarding the eligibility of Priority Review Vouchers. These forward-looking statements reflect the current expectations of the Company’s management regarding future growth, results of operations, performance and business prospects and opportunities and involve known and unknown risks, uncertainties and assumptions, including, without limitation. limit themselves to it, (i) the risks associated with unforeseen events likely to delay or hinder the Company’s development plans with regard to its product portfolio, (ii) the risk that a product may ultimately be not eligible for the priority review voucher and (iii) the risks and assumptions listed in the Company’s annual information form dated
Phone. : 1-646-717-9915